201 related articles for article (PubMed ID: 36243494)
61. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes.
Jonson SD; Bonasera TA; Dehdashti F; Cristel ME; Katzenellenbogen JA; Welch MJ
Nucl Med Biol; 1999 Jan; 26(1):123-30. PubMed ID: 10096512
[TBL] [Abstract][Full Text] [Related]
62. Biodistribution of
Iqbal R; Yaqub M; Oprea-Lager DE; Liu Y; Luik AM; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
J Nucl Med; 2022 May; 63(5):694-699. PubMed ID: 34446451
[TBL] [Abstract][Full Text] [Related]
63. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
van Kruchten M; de Vries EG; Glaudemans AW; van Lanschot MC; van Faassen M; Kema IP; Brown M; Schröder CP; de Vries EF; Hospers GA
Cancer Discov; 2015 Jan; 5(1):72-81. PubMed ID: 25380844
[TBL] [Abstract][Full Text] [Related]
64. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
[TBL] [Abstract][Full Text] [Related]
65. PET Imaging of Breast Cancer: Role in Patient Management.
Lebron L; Greenspan D; Pandit-Taskar N
PET Clin; 2015 Apr; 10(2):159-95. PubMed ID: 25829085
[TBL] [Abstract][Full Text] [Related]
66. 18F-Fluoroestradiol.
Sundararajan L; Linden HM; Link JM; Krohn KA; Mankoff DA
Semin Nucl Med; 2007 Nov; 37(6):470-6. PubMed ID: 17920354
[TBL] [Abstract][Full Text] [Related]
67. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging.
Aliaga A; Rousseau JA; Ouellette R; Cadorette J; van Lier JE; Lecomte R; Bénard F
Nucl Med Biol; 2004 Aug; 31(6):761-70. PubMed ID: 15246367
[TBL] [Abstract][Full Text] [Related]
68. Automated SPE-based synthesis of 16α-[
Fedorova O; Nikolaeva V; Krasikova R
Appl Radiat Isot; 2018 Nov; 141():57-63. PubMed ID: 30176563
[TBL] [Abstract][Full Text] [Related]
69. Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.
Venema CM; Apollonio G; Hospers GA; Schröder CP; Dierckx RA; de Vries EF; Glaudemans AW
Clin Nucl Med; 2016 Nov; 41(11):844-851. PubMed ID: 27607175
[TBL] [Abstract][Full Text] [Related]
70. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals.
Seimbille Y; Rousseau J; Bénard F; Morin C; Ali H; Avvakumov G; Hammond GL; van Lier JE
Steroids; 2002 Aug; 67(9):765-75. PubMed ID: 12123788
[TBL] [Abstract][Full Text] [Related]
71. Molecular Imaging and Precision Medicine in Breast Cancer.
Chudgar AV; Mankoff DA
PET Clin; 2017 Jan; 12(1):39-51. PubMed ID: 27863565
[TBL] [Abstract][Full Text] [Related]
72. To Identify Small Bowel Metastasis From Lobular Breast Cancer on 18 F-Fluoroestradiol PET/CT : Necessary to Adjust the Background Uptake Level.
Lu Y
Clin Nucl Med; 2023 Feb; 48(2):192-193. PubMed ID: 36083216
[TBL] [Abstract][Full Text] [Related]
73. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract][Full Text] [Related]
74. Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes.
Grabher BJ
J Nucl Med Technol; 2020 Sep; 48(3):191-201. PubMed ID: 32111662
[TBL] [Abstract][Full Text] [Related]
75. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.
Wang CL; MacDonald LR; Rogers JV; Aravkin A; Haseley DR; Beatty JD
AJR Am J Roentgenol; 2011 Aug; 197(2):W247-55. PubMed ID: 21785049
[TBL] [Abstract][Full Text] [Related]
76.
Xu D; Zhuang R; You L; Guo Z; Wang X; Peng C; Zhang D; Zhang P; Wu H; Pan W; Zhang X
Nucl Med Biol; 2018 Apr; 59():48-55. PubMed ID: 29466767
[TBL] [Abstract][Full Text] [Related]
77. PET Imaging of Estrogen Receptors for Gynecological Tumors.
Tsujikawa T; Makino A; Mori T; Tsuyoshi H; Kiyono Y; Yoshida Y; Okazawa H
Clin Nucl Med; 2022 Jul; 47(7):e481-e488. PubMed ID: 35675139
[TBL] [Abstract][Full Text] [Related]
78. Metastatic invasive lobular breast cancer presenting as linitis plastica of the colon: Tumour characterization using [
Tsujikawa T; Takahashi M; Maeda H; Mori T; Makino A; Kiyono Y; Imamura Y; Goi T; Okazawa H
J Med Imaging Radiat Oncol; 2022 Aug; 66(5):634-636. PubMed ID: 34545689
[TBL] [Abstract][Full Text] [Related]
79. 18F-FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer.
Venema C; de Vries E; Glaudemans A; Poppema B; Hospers G; Schröder C
Clin Nucl Med; 2017 Aug; 42(8):612-614. PubMed ID: 28604479
[TBL] [Abstract][Full Text] [Related]
80. One-Step
Huang H; Li K; Lv G; Liu G; Zhao X; Liu Q; Wang S; Li X; Qiu L; Lin J
Contrast Media Mol Imaging; 2018; 2018():5362329. PubMed ID: 29692688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
